single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s ...

Novo Nordisk launched a direct-to-consumer program last week to ... NovoCare also offers home deliveries and refill reminders for Wegovy prescriptions. This initiative comes after the Food and Drug ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.

Bagsværd, Denmark, 10 March 2025 - Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen ...

Novo Nordisk ... of Novo Nordisk Inc. “With NovoCare Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy at a reduced ...

LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...

Shares of Novo Nordisk dropped Monday after the company reported that its next-generation obesity drug produced weight loss results in diabetes patients that fell short of investors ...